← Leaderboards
Michael L Camilleri
Mayo Clinic Coll Of Medicine, Rochester
$18,731,842
Attributed
$19,846,736
Total exposure
36
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$19,846,736 · 36
By mechanism
R01$16,351,750 · 9
K24$1,127,698 · 1
RC1$1,000,000 · 1
M01$744,069 · 23
R56$395,669 · 1
U54$227,550 · 1
Top collaborators
- Pankaj J Pasricha4 shared
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectIrritable Bowel SyndromeSymptomsGastrointestinal FunctionMotorStomachPharmaceutical PreparationsFunctional DisorderGastrointestinal Motility /PressureGastric EmptyingGastrointestinal Disorder ChemotherapyResponsePlacebosBaseConstipationGenotypeGastrointestinalSatiationDiarrheaFutureSolidGenesAffect
Grant awards (100)
Parkinson Disease Neural Circuitry and Gastrointestinal Pathobiology$610,734
R01 · FY2025 · DK · contact PI
A Randomized, placebo-controlled trial of the effects of Long-Acting GLP-1 or Dual Incretin (GLP-1 and GIP) Modulation on Gastrointestinal Functions and Relationship to Weight Loss$322,800
R01 · FY2025 · DK · contact PI
Parkinson Disease Neural Circuitry and Gastrointestinal Pathobiology$561,762
R01 · FY2024 · DK · contact PI
A randomized control trial of G-POEM for gastroparesis to assess feasibility, safety, efficacy and physiological mechanisms$518,756
R01 · FY2024 · DK
Effect of VNS on Gastric Motor Functions$75,938
U54 · FY2024 · AT · contact PI
Parkinson Disease Neural Circuitry and Gastrointestinal Pathobiology$584,292
R01 · FY2023 · DK · contact PI
A randomized control trial of G-POEM for gastroparesis to assess feasibility, safety, efficacy and physiological mechanisms$510,733
R01 · FY2023 · DK
Effect of VNS on Gastric Motor Functions$75,806
U54 · FY2023 · AT · contact PI
A randomized control trial of G-POEM for gastroparesis to assess feasibility, safety, efficacy and physiological mechanisms$593,950
R01 · FY2022 · DK
Pharmacodynamics, Pharmacogenetics, Clinical Efficacy and Safety of Cannabidiol for Gastroparesis and Functional Dyspepsia$373,154
R01 · FY2022 · DK · contact PI
Effect of VNS on Gastric Motor Functions$75,806
U54 · FY2022 · AT · contact PI
A randomized control trial of G-POEM for gastroparesis to assess feasibility, safety, efficacy and physiological mechanisms$606,350
R01 · FY2021 · DK
Genetic Control and Ileo-Colonic Mucosal Expression of Bile Acid-Related Mechanisms in Irritable Bowel Syndrome-Diarrhea$459,234
R01 · FY2021 · DK · contact PI
Pharmacodynamics, Pharmacogenetics, Clinical Efficacy and Safety of Cannabidiol for Gastroparesis and Functional Dyspepsia$373,154
R01 · FY2021 · DK · contact PI
Genetic Control and Ileo-Colonic Mucosal Expression of Bile Acid-Related Mechanisms in Irritable Bowel Syndrome-Diarrhea$453,924
R01 · FY2020 · DK · contact PI
Pharmacodynamics, Pharmacogenetics, Clinical Efficacy and Safety of Cannabidiol for Gastroparesis and Functional Dyspepsia$373,154
R01 · FY2020 · DK · contact PI
Effects of Liraglutide on Gastric Functions and their Relationship to Weight Loss in Obesity$317,078
R01 · FY2020 · DK · contact PI
Effects of Liraglutide on Gastric Functions and their Relationship to Weight Loss in Obesity$514,059
R01 · FY2019 · DK · contact PI
Genetic Control and Ileo-Colonic Mucosal Expression of Bile Acid-Related Mechanisms in Irritable Bowel Syndrome-Diarrhea$449,570
R01 · FY2019 · DK · contact PI
Pharmacodynamics, Pharmacogenetics, Clinical Efficacy and Safety of Cannabidiol for Gastroparesis and Functional Dyspepsia$373,154
R01 · FY2019 · DK · contact PI
Effects of Liraglutide on Gastric Functions and their Relationship to Weight Loss in Obesity$514,059
R01 · FY2018 · DK · contact PI
Genetic Control and Ileo-Colonic Mucosal Expression of Bile Acid-Related Mechanisms in Irritable Bowel Syndrome-Diarrhea$464,532
R01 · FY2018 · DK · contact PI
Effects of Liraglutide on Gastric Functions and their Relationship to Weight Loss in Obesity$514,444
R01 · FY2017 · DK · contact PI
Pharmacogenomics of Gastric Function & Weight in Obesity$395,669
R56 · FY2015 · DK · contact PI
Bile Acids, Genetic Control and Colonic Function in Irritable Bowel Syndrome$342,998
R01 · FY2015 · DK · contact PI
Bile Acids, Genetic Control and Colonic Function in Irritable Bowel Syndrome$342,998
R01 · FY2014 · DK · contact PI
Pharmacogenomics of Gastric Function & Weight in Obesity$223,446
R01 · FY2014 · DK · contact PI
Bile Acids, Genetic Control and Colonic Function in Irritable Bowel Syndrome$330,993
R01 · FY2013 · DK · contact PI
Pharmacogenomics of Gastric Function & Weight in Obesity$311,742
R01 · FY2013 · DK · contact PI
Bile Acids, Genetic Control and Colonic Function in Irritable Bowel Syndrome$342,998
R01 · FY2012 · DK · contact PI
Pharmacogenomics of Gastric Function & Weight in Obesity$323,075
R01 · FY2012 · DK · contact PI
Bile Acids, Genetic Control and Colonic Function in Irritable Bowel Syndrome$394,250
R01 · FY2011 · DK · contact PI
Pharmacogenomics of Gastric Function & Weight in Obesity$323,101
R01 · FY2011 · DK · contact PI
Irritable bowel syndrome-diarrhea: the role of gluten intolerance and HLA-DQ2$500,000
RC1 · FY2010 · DK · contact PI
Pharmacogenomics of Gastric Function & Weight in Obesity$393,240
R01 · FY2010 · DK · contact PI
Cannabinoid Mechanisms in Human Gastrointestinal Motor and Sensory Functions$376,248
R01 · FY2010 · DK · contact PI
Irritable bowel syndrome-diarrhea: the role of gluten intolerance and HLA-DQ2$500,000
RC1 · FY2009 · DK · contact PI
Cannabinoid Mechanisms in Human Gastrointestinal Motor and Sensory Functions$375,947
R01 · FY2009 · DK · contact PI
Pharmacogenomics of Gastric Function & Weight in Obesity$239,854
R01 · FY2008 · DK · contact PI
Alpha 2 Adrenergic Control in Irritable Bowel Syndrome$139,598
K24 · FY2008 · DK · contact PI
Pharmacogenomics of Gastric Function & Weight in Obesity$244,750
R01 · FY2007 · DK · contact PI
Alpha-2 Adrenergic Control of Colonic Function in IBS$228,417
R01 · FY2007 · DK · contact PI
Alpha 2 Adrenergic Control in Irritable Bowel Syndrome$139,598
K24 · FY2007 · DK · contact PI
Pharmacogenomics of Gastric Function & Weight in Obesity$252,060
R01 · FY2006 · DK · contact PI
Alpha-2 Adrenergic Control of Colonic Function in IBS$235,240
R01 · FY2006 · DK · contact PI
Alpha 2 Adrenergic Control in Irritable Bowel Syndrome$139,598
K24 · FY2006 · DK · contact PI
Pharmacogenomics of Gastric Function &Weight in Obesity$258,125
R01 · FY2005 · DK
Alpha-2 Adrenergic Control of Colonic Function in IBS$240,900
R01 · FY2005 · DK
Alpha 2 Adrenergic Control in Irritable Bowel Syndrome$139,468
K24 · FY2005 · DK
EFFECT OF MACRONUTRIENT PRELOAD ON GASTRIC SENSORY AND MOTOR FUNCTIONS$119,183
M01 · FY2005 · RR
THE EFFECT OF ALVIMOPAN ON GI TRANSIT IN HEALTHY SUBJECTS$91,223
M01 · FY2005 · RR
EFFECT OF A CHLORIDE CHANNEL ACTIVATOR ON GASTRIC SENSORY AND MOTOR FUNCTIONS$58,762
M01 · FY2005 · RR
ALPHA-2 ADRENERGIC CONTROL OF COLONIC FUNCTION IN IRRITABLE BOWEL SYNDROME$57,341
M01 · FY2005 · RR
VSL #3 ON SYMPTOMS AND COLONIC TRANSIT IN PATIENTS WITH ABDOMINAL BLOATING$53,312
M01 · FY2005 · RR
EFFECT OF A MOTILIN AGONIST, BAX-ACC-1638, ON GASTROINTESTINAL MOTOR FUNCTIONS$37,674
M01 · FY2005 · RR
EFFECTS OF THE SYNTHETIC OREXIN, GHRELIN, ON GASTRIC MOTOR FUNCTIONS$7,819
M01 · FY2005 · RR
DEXLOXIGLUMIDE ON SMALL BOWEL AND COLONIC TRANSIT IN FEMALE PATIENTS WITH C-IBS$3,080
M01 · FY2005 · RR
STUDY OF GASTROINTESTINAL SYMPTOMS, EARLY SATIETY TEST AND GASTRIC ACCOMMODATION$1,422
M01 · FY2005 · RR
EFFECT OF DRONABINOL ON COLONIC SENSORIMOTOR FUNCTIONS IN HEALTHY SUBJECTS$474
M01 · FY2005 · RR
Pharmacogenomics of Gastric Function &Weight in Obesity$258,125
R01 · FY2004 · DK
Alpha-2 Adrenergic Control of Colonic Function in IBS$240,900
R01 · FY2004 · DK
Alpha 2 Adrenergic Control in Irritable Bowel Syndrome$136,192
K24 · FY2004 · DK
Genetic Epidemiology and Pathophysiology of Dyspepsia$68,596
M01 · FY2004 · RR
SB-223412, and NK3 Antagonist, on Rectal Sensorimotor Fu$66,278
M01 · FY2004 · RR
Dexloxiglumide/Small Bowel &Colonic Transit in C-IBS$63,497
M01 · FY2004 · RR
Renzapride on Gastrointestinal Transit in C-IBS Patients$49,130
M01 · FY2004 · RR
VSL #3 on Symptoms/Colonic Transit in Abdominal Bloating$27,345
M01 · FY2004 · RR
Functional Dyspepsia /Upper Recurrent Abdominal Pain$18,771
M01 · FY2004 · RR
Relationship of Gastric Emptying/Accommodation/Meal Size$9,270
M01 · FY2004 · RR
Effect of Alvimopan on GI Transit in Healthy Subjects$4,635
M01 · FY2004 · RR
Lower Recurrent Abdominal Pain and Constipation$3,245
M01 · FY2004 · RR
GI Symptoms, early Satiety Test &Gastric Accommodation$3,012
M01 · FY2004 · RR
Alpha-2 Adrenergic Control of Colonic Function in IBS$240,900
R01 · FY2003 · DK
ALPHA 2 ADRENERGIC CONTROL IN IRRITABLE BOWEL SYNDROME$108,311
K24 · FY2003 · DK
ALPHA 2 ADRENERGIC CONTROL IN IRRITABLE BOWEL SYNDROME$108,311
K24 · FY2002 · DK
AMYLIN ANALOG AND GASTROINTESTAL AND COLONIC TRANSIT$0
M01 · FY2002 · RR
ALOSETRON AND GI /COLONIC TRANSIT IN NONCONSTIPATED IBS$0
M01 · FY2002 · RR
LOCALLY DELIVERED PYRIDOSTIGMINE BROMIDE &COLONIC MOTIL$0
M01 · FY2002 · RR
ALPHA-2 ADRENERGIC CONTROL OF COLONIC FUNCTION IN IBS$0
M01 · FY2002 · RR
R108512 AND GI/COLONIC TRANSIT IN FUNCTIONAL CONSTIPATION OR IBS$0
M01 · FY2002 · RR
EFFECT OF NEUROKININ 2 RECEPTOR ANTAGONIST (SR48968C) ON RECTAL SENSATION$0
M01 · FY2002 · RR
EFFECT OF RECOMBINANT METHIONYL HUMAN NEUROTROPHIN 3 ON GI MOTILITY$0
M01 · FY2002 · RR
ALPHA 2 ADRENERGIC CONTROL OF COLONIC FUNCTION IN IBS$173,105
R01 · FY2001 · DK
ALPHA 2 ADRENERGIC CONTROL IN IRRITABLE BOWEL SYNDROME$108,311
K24 · FY2001 · DK
LOCALLY DELIVERED PYRIDOSTIGMINE BROMIDE &COLONIC MOTIL$0
M01 · FY2001 · RR
ALPHA-2 ADRENERGIC CONTROL OF COLONIC FUNCTION IN IBS$0
M01 · FY2001 · RR
R108512 AND GI/COLONIC TRANSIT IN FUNCTIONAL CONSTIPATION OR IBS$0
M01 · FY2001 · RR
EFFECT OF NEUROKININ 2 RECEPTOR ANTAGONIST (SR48968C) ON RECTAL SENSATION$0
M01 · FY2001 · RR
EFFECT OF RECOMBINANT METHIONYL HUMAN NEUROTROPHIN 3 ON GI MOTILITY$0
M01 · FY2001 · RR
AMYLIN ANALOG AND GASTROINTESTAL AND COLONIC TRANSIT$0
M01 · FY2001 · RR
ALOSETRON AND GI /COLONIC TRANSIT IN NONCONSTIPATED IBS$0
M01 · FY2001 · RR
ALPHA 2 ADRENERGIC CONTROL OF COLONIC FUNCTION IN IBS$169,445
R01 · FY2000 · DK
ALPHA 2 ADRENERGIC CONTROL IN IRRITABLE BOWEL SYNDROME$108,311
K24 · FY2000 · DK
ALOSETRON AND GI /COLONIC TRANSIT IN NONCONSTIPATED IBS$0
M01 · FY2000 · RR
LOCALLY DELIVERED PYRIDOSTIGMINE BROMIDE &COLONIC MOTIL$0
M01 · FY2000 · RR
ALPHA-2 ADRENERGIC CONTROL OF COLONIC FUNCTION IN IBS$0
M01 · FY2000 · RR
AMYLIN ANALOG AND GASTROINTESTAL AND COLONIC TRANSIT$0
M01 · FY2000 · RR
R108512 AND GI/COLONIC TRANSIT IN FUNCTIONAL CONSTIPATION OR IBS$0
M01 · FY2000 · RR
EFFECT OF NEUROKININ 2 RECEPTOR ANTAGONIST (SR48968C) ON RECTAL SENSATION$0
M01 · FY2000 · RR
EFFECT OF RECOMBINANT METHIONYL HUMAN NEUROTROPHIN 3 ON GI MOTILITY$0
M01 · FY2000 · RR